{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:20:14Z","timestamp":1791228014392,"version":"4.1.0"},"reference-count":60,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Radiolabeled fibroblast activation protein inhibitors (FAPIs) have emerged as novel radiopharmaceutical agents for tumor diagnosis. Compared with [18F]fluoro-2-deoxy-D-glucose ([18F]FDG), which reflects glucose uptake in metabolically active regions, FAPIs mainly bind to the fibroblast activation protein (FAP), which is highly expressed in tumor-associated fibroblasts, forming a pronounced signal. Several studies suggested potential superiority of FAPI tracers above [18F]FDG-based imaging in a variety of tumor entities. In this systematic review, we focus on the comparison of FAPI-PET\/CT and [18F]FDG-PET\/CT in upper-abdominal tumors. Methods: Original research published from 1 January 2021 to 22 December 2024 was collected from the PubMed and Web of Science databases (CRD42025648267). This research included only clinical studies, excluding conference abstracts and case reports. The risk of bias was assessed with the QUADAS-2 tool, and all evaluation steps performed independently by three independent reviewers. A systematic quality assessment of the included studies was conducted based on the imaging performance of FAPI-PET\/CT and [18F]FDG-PET\/CT for pancreatic, liver, and gastric cancers. The meta-analysis used relative risk (RR) as the effect size, with bias assessed via the Peters test (p-value &gt; 0.05). Cochran\u2019s Q test and I-squared value are used to comprehensively evaluate the magnitude of heterogeneity. Analyses and data visualization were performed in R language. Results: The database search identified 3272 articles. After screening, 31 studies were included in this analysis. The original studies enrolled 1377 participants (M\/F: 850\/527; ages predominantly between 50 and 70). Of these, 939 patients were ultimately diagnosed with tumors (five cancer subtypes) and included in this analysis. Meta-analysis results showed that FAPI-PET\/CT significantly surpassed [18F]FDG-PET\/CT in the detection of primary lesions (RRs = 1.20 and 1.17), lymph nodes (RRs = 1.18 and 1.24), distant metastases (RRs = 1.22 and 1.51), peritoneal metastases (RRs = 1.31 and 2.22), and bone metastases (RRs = 1.16 and 1.23). The two imaging methods exhibit clear differences in diagnostic performance (sensitivity: 98% vs. 79%; specificity: 83% vs. 87%), and FAPI-PET\/CT demonstrates high and stable diagnostic performance (RRs = 1.20 and 1.17). Conclusions: Compared with [18F]FDG-PET\/CT, FAPI-PET\/CT demonstrates significant advantages in detecting primary lesions, lymph nodes, distant metastases, and peritoneal and bone metastases in pancreatic, liver, and gastric cancers (RR &gt; 1.0). Overall, FAPI-PET\/CT shows better diagnostic performance (RR &gt; 1.0).<\/jats:p>","DOI":"10.3390\/diagnostics16040520","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T14:05:15Z","timestamp":1770645915000},"page":"520","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Diagnostic Efficacy of FAPI-PET\/CT Versus [18F]FDG-PET\/CT in Upper-Abdominal Malignancies: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"16","author":[{"given":"Hao","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital RWTH Aachen, 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bet\u00fcl","family":"Altunay","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital RWTH Aachen, 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8198-5215","authenticated-orcid":false,"given":"Laura","family":"Sch\u00e4fer","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital RWTH Aachen, 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Boy","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital RWTH Aachen, 52074 Aachen, Germany"},{"name":"Center for Integrated Oncology (CIO), University Hospital RWTH Aachen, 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"von Mallek","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital RWTH Aachen, 52074 Aachen, Germany"},{"name":"Center for Integrated Oncology (CIO), University Hospital RWTH Aachen, 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7212-6521","authenticated-orcid":false,"given":"Felix M.","family":"Mottaghy","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital RWTH Aachen, 52074 Aachen, Germany"},{"name":"Center for Integrated Oncology (CIO), University Hospital RWTH Aachen, 52074 Aachen, Germany"},{"name":"Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"L\u00fctje","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital RWTH Aachen, 52074 Aachen, Germany"},{"name":"Center for Integrated Oncology (CIO), University Hospital RWTH Aachen, 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"226","article-title":"Beyond fluorodeoxyglucose: Molecular imaging of cancer in precision medicine","volume":"75","author":"Juweid","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00259-017-3687-3","article-title":"Evaluating tumor response with FDG PET: Updates on PERCIST, comparison with EORTC criteria and clues to future developments","volume":"44","author":"Pinker","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40336-019-00347-y","article-title":"Management of hyperglycemia in oncological patients scheduled for an FDG-PET\/CT examination","volume":"7","author":"Evangelista","year":"2019","journal-title":"Clin. Transl. Imaging"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2021.01.008","article-title":"Consensus on molecular imaging and theranostics in neuroendocrine neoplasms","volume":"146","author":"Ambrosini","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1007\/s00259-021-05211-8","article-title":"PET\/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC-current state and future directions","volume":"48","author":"Eze","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.semnuclmed.2021.06.008","article-title":"Limitations and Pitfalls of FDG-PET\/CT in Infection and Inflammation","volume":"51","author":"Pijl","year":"2021","journal-title":"Semin. Nucl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.semnuclmed.2022.06.001","article-title":"Response Evaluation Following Radiation Therapy with 18F-FDG PET\/CT: Common Variants of Radiation-Induced Changes and Potential Pitfalls","volume":"52","author":"Dejanovic","year":"2022","journal-title":"Semin. Nucl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1053\/j.semnuclmed.2023.11.003","article-title":"How to Perform FAPI PET? An Expedited Systematic Review Providing a Recommendation for FAPI PET Imaging with Different FAPI Tracers","volume":"54","author":"Bentestuen","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","article-title":"Fibroblast activation protein-targeted radionuclide therapy: Background, opportunities, and challenges of first (pre)clinical studies","volume":"50","author":"Boussihmad","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2967\/jnumed.120.244806","article-title":"The Latest Developments in Imaging of Fibroblast Activation Protein","volume":"62","author":"Altmann","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health and malignancy","volume":"39","author":"Fitzgerald","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.3748\/wjg.v17.i46.5059","article-title":"Role of 18F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies","volume":"17","author":"Smyth","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3748\/wjg.v25.i11.1289","article-title":"Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma","volume":"25","author":"Lee","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.7150\/thno.69475","article-title":"Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review","volume":"12","author":"Zhao","year":"2022","journal-title":"Theranostics"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00259-021-05488-9","article-title":"FAP imaging in rare cancer entities-first clinical experience in a broad spectrum of malignancies","volume":"49","author":"Dendl","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00259-024-06943-z","article-title":"Preoperative assessment of pancreatic cancer with [68Ga]Ga-DOTA-FAPI-04 PET\/MR versus [18F]-FDG PET\/CT plus contrast-enhanced CT: A prospective preliminary study","volume":"52","author":"Zhang","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2967\/jnumed.123.266283","article-title":"18F-FAPI-04 Outperforms 18F-FDG PET\/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma","volume":"65","author":"Li","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1007\/s00330-023-09445-y","article-title":"The added value of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in pancreatic cancer: A comparison to [18F]F-FDG","volume":"33","author":"Liu","year":"2023","journal-title":"Eur. Radiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1007\/s00259-023-06297-y","article-title":"Comparing the clinical value of baseline [68Ga]Ga-FAPI-04 PET\/CT and [18F]F-FDG PET\/CT in pancreatic ductal adenocarcinoma: Additional prognostic value of the distal pancreatitis","volume":"50","author":"Ding","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1007\/s00259-021-05576-w","article-title":"Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer","volume":"49","author":"Pang","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1007\/s00259-023-06137-z","article-title":"Clinical prospective study of Gallium 68 (68Ga)\u2013labeled fibroblast-activation protein inhibitor PET\/CT in the diagnosis of biliary tract carcinoma","volume":"50","author":"Li","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13550-024-01145-y","article-title":"Role of [18F]FAPI-04 in staging and therapeutic management of intrahepatic cholangiocarcinoma: Prospective comparison with [18F]FDG PET\/CT","volume":"14","author":"Liang","year":"2024","journal-title":"EJNMMI Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s00259-020-05095-0","article-title":"Imaging fibroblast activation protein in liver cancer: A single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET\/CT versus MRI and [18F]-FDG PET\/CT","volume":"48","author":"Guo","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Liang, Z., Peng, H., Li, W., and Liu, Z. (2024). Head-to-head study of [18F]FAPI-04 PET\/CT and [18F]FDG PET\/CT for non-invasive assessment of liver cancer and its immunohistochemical markers. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-13153-1"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1007\/s00330-024-11219-z","article-title":"Evaluating the diagnostic performance of [18F]ALF-NOTA-FAPI-04 PET\/CT in gastric cancer: A comparative study with [18F]FDG PET\/CT","volume":"35","author":"Lv","year":"2025","journal-title":"Eur. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Yang, J., Wu, Y., Zhang, Y., Peng, X., Jiang, C., Zhou, W., Dai, J., Xie, A., Ye, H., and Zheng, K. (2024). Comparative assessment of the diagnostic efficacy of [18F]AlF-NOTA-FAPI-04 and [18F]FDG PET\/CT imaging for detecting postoperative recurrence in gastric cancer patients: A pilot study. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1427649"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s00259-021-05441-w","article-title":"Comparison of [68Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: A bicentric retrospective study","volume":"49","author":"Jiang","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.120.258467","article-title":"68Ga-DOTA-FAPI-04 PET\/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET\/CT","volume":"63","author":"Qin","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1148\/radiol.2020203275","article-title":"Comparison of 68Ga-FAPI and 18F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers","volume":"298","author":"Pang","year":"2021","journal-title":"Radiology"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Wang, H., Zhu, W., Ren, S., Kong, Y., Huang, Q., Zhao, J., Guan, Y., Jia, H., Chen, J., and Lu, L. (2021). 68Ga-FAPI-04 Versus 18F-FDG PET\/CT in the Detection of Hepatocellular Carcinoma. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.693640"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00259-021-05494-x","article-title":"Head-to-head comparison of [68Ga]Ga-FAPI-04 and [18F]-FDG PET\/CT in evaluating the extent of disease in gastric adenocarcinoma","volume":"49","author":"Kuten","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1007\/s00259-022-05799-5","article-title":"[68Ga]Ga-DOTA-FAPI-04 PET\/CT in the evaluation of gastric cancer: Comparison with [18F]FDG PET\/CT","volume":"49","author":"Lin","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1007\/s00259-022-05729-5","article-title":"Comparison of the diagnostic efficacy of 68Ga-FAPI-04 PET\/MR and 18F-FDG PET\/CT in patients with pancreatic cancer","volume":"49","author":"Zhang","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Zhang, S., Wang, W., Xu, T., Ding, H., Li, Y., Liu, H., Huang, Y., Liu, L., Du, T., and Zhao, Y. (2022). Comparison of Diagnostic Efficacy of [68Ga]Ga-FAPI-04 and [18F]FDG PET\/CT for Staging and Restaging of Gastric Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.925100"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s00259-022-05955-x","article-title":"[18F]FAPI-42 PET\/CT versus [18F]FDG PET\/CT for imaging of recurrent or metastatic gastrointestinal stromal tumors","volume":"50","author":"Wu","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00330-022-09084-9","article-title":"Comparison of [68Ga]Ga-FAPI and [18F]FDG uptake in patients with gastric signet-ring-cell carcinoma: A multicenter retrospective study","volume":"33","author":"Chen","year":"2023","journal-title":"Eur. Radiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1007\/s00330-022-09251-y","article-title":"Usefulness of [68Ga]FAPI-04 and [18F]FDG PET\/CT for the detection of primary tumour and metastatic lesions in gastrointestinal carcinoma: A comparative study","volume":"33","author":"Li","year":"2023","journal-title":"Eur. Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1007\/s00330-022-09321-1","article-title":"Utility of [68Ga]FAPI-04 and [18F]FDG dual-tracer PET\/CT in the initial evaluation of gastric cancer","volume":"33","author":"Miao","year":"2023","journal-title":"Eur. Radiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1097\/RLU.0000000000004641","article-title":"Role of 68Ga-FAPI PET\/CT in Assessing Hepatobiliary Malignancies: A Prospective Pilot Study","volume":"48","author":"Rajaraman","year":"2023","journal-title":"Clin. Nucl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40644-023-00596-1","article-title":"Clinical application of Al18F-NOTA-FAPI PET\/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to 18F-FDG","volume":"23","author":"Lyu","year":"2023","journal-title":"Cancer Imaging"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40644-023-00626-y","article-title":"Head-to-head comparison of 18F-FAPI and 18F-FDG PET\/CT in staging and therapeutic management of hepatocellular carcinoma","volume":"23","author":"Zhang","year":"2023","journal-title":"Cancer Imaging"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.2967\/jnumed.122.264827","article-title":"68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial","volume":"64","author":"Kessler","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/RLU.0000000000005112","article-title":"68Ga-FAPI-04 PET\/CT for the Evaluation of Cholangiocarcinoma: Comparison with 18F-FDG PET\/CT and Abdominal 68Ga-FAPI-04 PET\/MR","volume":"49","author":"Zhang","year":"2024","journal-title":"Clin. Nucl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2967\/jnumed.123.266329","article-title":"Fibroblast Activation Protein-Targeted PET\/CT with 18F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with 18F-FDG PET\/CT","volume":"65","author":"Xu","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1007\/s11307-024-01950-w","article-title":"Prospective Comparison of [18F]FDG and [18F]AIF-FAPI-74 PET\/CT in the Evaluation of Potentially Resectable Pancreatic Ductal Adenocarcinoma","volume":"26","author":"Yun","year":"2024","journal-title":"Mol. Imaging Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e230195","DOI":"10.1148\/rycan.230195","article-title":"Assessing the Value of 68Ga-FAPI PET\/CT in Gastric Mucinous Adenocarcinoma or Signet Ring Cell Carcinoma","volume":"6","author":"Sun","year":"2024","journal-title":"Radiol. Imaging Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.fob.2013.12.001","article-title":"Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs","volume":"4","author":"Keane","year":"2013","journal-title":"FEBS Open Bio"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2967\/jnumed.121.262426","article-title":"Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study","volume":"63","author":"Mona","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00048.2019","article-title":"Diversity and Biology of Cancer-Associated Fibroblasts","volume":"101","author":"Biffi","year":"2021","journal-title":"Physiol. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.semcancer.2022.04.008","article-title":"Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging","volume":"86","author":"Peltier","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"20220463","DOI":"10.1259\/bjr.20220463","article-title":"Non-oncologic incidental uptake on FAPI PET\/CT imaging","volume":"96","author":"Hotta","year":"2023","journal-title":"Br. J. Radiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1097\/RLU.0000000000005348","article-title":"Recent Clinical Implications of FAPI: Imaging and Therapy","volume":"49","author":"Kiani","year":"2024","journal-title":"Clin. Nucl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s12149-021-01673-w","article-title":"Characterization of the benign lesions with increased 68Ga-FAPI-04 uptake in PET\/CT","volume":"35","author":"Zheng","year":"2021","journal-title":"Ann. Nucl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.7150\/thno.106108","article-title":"Therapeutic potential of FAPI RLT in oncology: A systematic review","volume":"15","author":"Ruzzeh","year":"2025","journal-title":"Theranostics"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e3312","DOI":"10.1002\/jgm.3312","article-title":"A brief introduction of meta-analyses in clinical practice and research","volume":"23","author":"Wang","year":"2021","journal-title":"J. Gene Med."},{"key":"ref_57","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00259-022-06052-9","article-title":"Current research topics in FAPI theranostics: A bibliometric analysis","volume":"50","author":"Keijsers","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3348\/kjr.2023.0840","article-title":"Imaging Evaluation of Peritoneal Metastasis: Current and Promising Techniques","volume":"25","author":"Fu","year":"2024","journal-title":"Korean J. Radiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/4\/520\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T14:24:05Z","timestamp":1770647045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/4\/520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":60,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["diagnostics16040520"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16040520","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]}}}